Description
Toceranib is a potent, cell-permeable, ATP-competitive multi-targeted receptor tyrosine kinase inhibitor that is structurally related to Sunitinib (Cat. No. 2097). It potently inhibits signaling through VEGFR, FGFR, PDGFR, and Kit. Additionally, toceranib blocks the autophosphorylation of both wild type and mutant forms of Kit in response to stem cell factor, resulting in cell death. It is active in vivo and is commonly used against solid tumors in dogs.
Toceranib is a potent, cell-permeable, ATP-competitive multi-targeted receptor tyrosine kinase inhibitor that is structurally related to Sunitinib (Cat. No. 2097). It potently inhibits signaling through VEGFR, FGFR, PDGFR, and Kit.
Alternate Name/Synonyms: 5-[(Z)-(5-Fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide; PHA 291639, SU 11654
Appearance: Orange solid
Formulation: N/A
CAS Number: 356068-94-5
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: N/A
Molecular Formula: C₂₂H₂₅FN₄O₂
Molecular Weight: 396.46
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO (~ 4 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: An ATP-competitive multi-targeted receptor tyrosine kinase inhibitor
MDL Number: N/A
PubChem CID: 5329106
SMILES: CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)C=C3C4=C(C=CC(=C4)F)NC3=O
InChi: InChI=1S/C22H25FN4O2/c1-13-19(12-17-16-11-15(23)5-6-18(16)26-21(17)28)25-14(2)20(13)22(29)24-7-10-27-8-3-4-9-27/h5-6,11-12,25H,3-4,7-10H2,1-2H3,(H,24,29)(H,26,28)/b17-12-
InChi Key: SRSGVKWWVXWSJT-ATVHPVEESA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |